In a patient with a myeloproliferative neoplasm, how should therapy be selected based on the specific driver mutation (JAK2 V617F, CALR, MPL, or triple‑negative)?

Treatment Selection in MPN Based on Driver Mutations

Treatment selection in myeloproliferative neoplasms should be based primarily on clinical risk stratification (age >60 years and/or prior thrombosis) rather than the specific driver mutation type (JAK2 V617F, CALR, MPL, or triple-negative), as current evidence-based guidelines do not recommend mutation-specific therapeutic algorithms. 1, 2

Risk-Stratified Treatment Approach

The European LeukemiaNet guidelines establish that clinical risk factors, not mutation status, drive treatment decisions in PV and ET:

High-Risk Disease (Age >60 years OR prior thrombosis):

• PV: Phlebotomy + low-dose aspirin + cytoreduction (hydroxyurea or interferon-alpha at any age) 1, 2
• ET: Cytoreduction with hydroxyurea at any age 1
• PMF: Risk stratification using IPSS/Dynamic IPSS plus cytogenetics and transfusion status 1

Low-Risk Disease (Age ≤60 years AND no prior thrombosis):

• PV: Phlebotomy + low-dose aspirin alone 1
• ET: Observation or low-dose aspirin for microvascular symptoms 3

Mutation-Specific Considerations

While treatment algorithms don't differ by mutation type, certain clinical patterns warrant attention:

JAK2 V617F-Positive Disease:

• Associated with higher thrombotic risk in some studies 4
• Present in >90% of PV, ~60% of ET/PMF 1
• No mutation-specific therapy indicated—treat based on clinical risk 1, 2

CALR-Mutated Disease:

• Younger age at presentation, more thrombocytosis, better survival in MF 2, 5
• Some retrospective data suggest low-risk CALR-mutated ET may not benefit from aspirin, but insufficient evidence to withhold aspirin 3
• Emerging CALR-targeted immunotherapies remain investigational 6, 5

MPL-Mutated Disease:

• Treat identically to other mutations based on clinical risk 1

Triple-Negative Disease:

• Search for complementary clonal markers (ASXL1, EZH2, IDH1/IDH2, SRSF2) to confirm clonal disease 2
• Same risk-stratified treatment approach applies 1, 2

Second-Line Therapy Selection

When hydroxyurea fails (defined by specific ELN criteria including inadequate count control, intolerance, or toxicity 1):

• PV: Interferon-alpha OR ruxolitinib 2
• ET: Anagrelide or interferon-alpha (avoid sequential cytotoxic agents due to leukemia risk) 1
• PMF: Ruxolitinib for intermediate-2/high-risk disease with splenomegaly 2

Critical Pitfalls to Avoid

1. Do not select therapy based solely on mutation type—this contradicts evidence-based guidelines 1, 2
2. Do not withhold aspirin in CALR-mutated ET despite limited retrospective data suggesting possible lack of benefit 3
3. Do not use multiple sequential cytotoxic agents in ET/PV due to increased leukemia risk 1
4. Do not routinely monitor JAK2 V617F allele burden—no indication for clinical follow-up 1

Emerging Mutation-Directed Approaches

While not yet standard of care, mutation-specific therapies are in development:

• CALR-targeted monoclonal antibodies, CAR-T, and vaccines show promise in early trials 6, 5
• These remain investigational and should only be used in clinical trial settings

The fundamental principle remains: treat the patient's clinical risk profile, not the mutation. The discovery of driver mutations has revolutionized MPN diagnosis but has not yet translated into mutation-specific treatment algorithms in routine practice 1, 2.